Description: How do you develop an accelerated underwriting program? The Accelerated Underwriting Program Development Seminar held in Tampa, Florida on May 22, 2019 answers this question through a series of sessions across various disciplines, including underwriting, actuarial, project management, marketing and data science. This article outlines the key takeaways from each of the industry experts.

Description: Oliver Wyman surveyed the life insurance industry in 2Q 2018 on emerging life PBR practices. Key takeaways and a deeper dive on select practices are provided.

Description: This article discusses the risk mix related mathematical rationale for national average ACA premium rates dropping for the first time in 2019.

Description: This article is a brief overview of what digital health is, how it is regulated, and who some of the big unicorns are.

Description: Book review of 'Necessary Endings'.

Description: An analysis of the revamped state sponsored retirement income pension gives insight into design and funding elements that might figure in reforming social security in the United States.

Description: This article is part of a 2 part series on real options analysis (ROA). Before you can understand the limitations of ROA, you must first understand the difference between risk and uncertainty. This article goes into detail explaining the vast differences between the two phenomena.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This is the second installment of a two-part series. Part I was published in the July 2023 issue of The Stepping Stone and provided guidance on how a new (re)insurance company can build an attractive work environment for actuarial talent. In part II we will focus on how to encourage those actuaries to remain with the company in the long run.

Description: This article delves into general insurance questions raised by the recent CrowdStrike disruption on computer systems worldwide.